The American Society of Hematology (ASH) will hold a workshop on gene editing July 14-15, 2016 in Washington, D.C. I regret I will not be able to attend, but interested parties may at least glean some information about the scope of the meeting by following the link to review the program.
The information there is necessarily limited, but it looks like most of the presentations will discuss the use of gene editing to modify cells for cellular therapy, or as gene therapy. There is no clear suggestion that germline editing will be discussed—nor, frankly, would I expect it to be, except in passing.
As I posted this past December 10, I don’t see unusual ethical concerns from the sort of work that is on the agenda. I’ll watch for any news from the workshop and comment further if warranted.